NEGXF (NexgenRx) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

What is NexgenRx LT-Debt-to-Total-Asset?

NexgenRx NEGXF 40 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.22 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NexgenRx's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

NexgenRx's long-term debt to total assets ratio declined from Mar. 2025 (0.01) to Mar. 2026 (0.01). It may suggest that NexgenRx is progressively becoming less dependent on debt to grow their business.

NexgenRx (OTCPK:NEGXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NexgenRx LT-Debt-to-Total-Asset Related Terms

NexgenRx LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for NexgenRx's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexgenRx LT-Debt-to-Total-Asset Chart

NexgenRx Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.02

0.01

NexgenRx Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

40GF Score

NexgenRx Inc NEGXF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

NexgenRx LT-Debt-to-Total-Asset Calculation

NexgenRx's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.207	/	26.529
	=	0.01

NexgenRx's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.208	/	29.782
	=	0.01

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.01 mean?

NexgenRx (NEGXF) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on NexgenRx and its competitors.

Is NexgenRx's LT-Debt-to-Total-Asset too high?

NexgenRx's current LT-Debt-to-Total-Asset is 0.01. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does NexgenRx's LT-Debt-to-Total-Asset compare to VEEV and BTSG?

NexgenRx's LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on NexgenRx and its competitors. NexgenRx's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is NexgenRx stock overvalued right now?

Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.33 — trading 47.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For NexgenRx (NEGXF), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 47.7% above its estimated GF Value™ of $0.22. GuruFocus considers NexgenRx to be Significantly Overvalued.

Key valuation signals for NEGXF:

LT-Debt-to-Total-Asset: 0.01
GF Value™: $0.22 vs. price of $0.33 (47.7% above fair value)
GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies TSXV:ADK NEOE:ALGO XCNQ:ALEN.U TSXV:PTEC XCNQ:APPT TSXV:KDA TSXV:SEGN XCNQ:AIML TSXV:CHS XCNQ:UDOC VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY

Other Exchanges NXG:Canada

Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6

Website https://www.nexgenrx.com

NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.

40GF Score

Get the complete analysis for NEGXF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33

Price

$0.22

GF Value

View NEGXF Analysis

See LT-Debt-to-Total-Asset data for all stocks →